ATAI Life Sciences BV (ATAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has a cash flow conversion efficiency ratio of -0.217x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.15 Million) by net assets ($222.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ATAI Life Sciences BV - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ATAI Life Sciences BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ATAI Life Sciences BV total liabilities for a breakdown of total debt and financial obligations.
ATAI Life Sciences BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sino Wealth Electronic Ltd
SHE:300327
|
0.035x |
|
Shoals Technologies Group Inc
NASDAQ:SHLS
|
0.033x |
|
Sichuan Haite High-tech Co Ltd
SHE:002023
|
0.002x |
|
Shaanxi Zhongtian Rocket Technology
SHE:003009
|
-0.001x |
|
Shandong Head Co Ltd
SHE:002810
|
0.028x |
|
Global Ship Lease Inc
NYSE:GSL
|
0.065x |
|
Sinosteel Engineering and Technology Co Ltd
SHE:000928
|
0.194x |
|
Science Environmental Protection Co. Ltd. A
SHG:688480
|
N/A |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences BV from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ATAI Life Sciences BV stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $222.00 Million | $-102.67 Million | -0.462x | +34.61% |
| 2024-12-31 | $116.55 Million | $-82.44 Million | -0.707x | -105.43% |
| 2023-12-31 | $244.32 Million | $-84.12 Million | -0.344x | +12.41% |
| 2022-12-31 | $265.77 Million | $-104.47 Million | -0.393x | -139.88% |
| 2021-12-31 | $385.96 Million | $-63.25 Million | -0.164x | +24.74% |
| 2020-12-31 | $95.37 Million | $-20.77 Million | -0.218x | -65.90% |
| 2019-12-31 | $59.78 Million | $-7.85 Million | -0.131x | -- |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more